| Literature DB >> 33921802 |
Vessela D Kancheva1, Maria Antonietta Dettori2, Davide Fabbri2, Petko Alov3, Silvia E Angelova4, Adriana K Slavova-Kazakova1, Paola Carta2, Valerii A Menshov5, Olga I Yablonskaya5, Aleksei V Trofimov5,6, Ivanka Tsakovska3, Luciano Saso7.
Abstract
Oxidative stress is associated with the increased production of reactive oxygen species or with a significant decrease in the effectiveness of antioxidant enzymes and nonenzymatic defense. The penetration of oxygen and free radicals in the hydrophobic interior of biological membranes initiates radical disintegration of the hydrocarbon "tails" of the lipids. This process is known as "lipid peroxidation", and the accumulation of the oxidation products as peroxides and the aldehydes and acids derived from them are often used as a measure of oxidative stress levels. In total, 40 phenolic antioxidants were selected for a comparative study and analysis of their chain-breaking antioxidant activity, and thus as modulators of oxidative stress. This included natural and natural-like ortho-methoxy and ortho-hydroxy phenols, nine of them newly synthesized. Applied experimental and theoretical methods (bulk lipid autoxidation, chemiluminescence, in silico methods such as density functional theory (DFT) and quantitative structure-activity relationship ((Q)SAR) modeling) were used to clarify their structure-activity relationship. Kinetics of non-inhibited and inhibited lipid oxidation in close connection with inhibitor transformation under oxidative stress is considered. Special attention has been paid to chemical reactions resulting in the initiation of free radicals, a key stage of oxidative stress. Effects of substituents in the side chains and in the phenolic ring of hydroxylated phenols and biphenols, and the concentration were discussed.Entities:
Keywords: bio-antioxidant; chain breaking antioxidant activity; oxidative stress; structure–activity relationship; synthesis
Year: 2021 PMID: 33921802 PMCID: PMC8074124 DOI: 10.3390/antiox10040624
Source DB: PubMed Journal: Antioxidants (Basel) ISSN: 2076-3921
Structures of all studied antioxidants.
|
| ||
|
| R |
|
| (A1) | ||
|
| –CH3 |
|
|
| –CHO |
|
|
| –COCH3 |
|
|
|
|
|
|
|
|
|
| (A2) | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| - |
| (A3) | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||
|
| R |
|
| (B1) | ||
|
|
|
|
| (B2) | ||
|
|
|
|
|
|
|
|
| (B3) | ||
|
|
|
|
Non-systematic and systematic names of the studied compounds are given in Table S1, Supporting Information.
Main kinetic parameters of chain-breaking antioxidant activity of the studied ortho-methoxyphenols (monomers and dimers) during lipid autoxidation.
| Abbr. | PF 0.1 mM | PF 1.0 mM | Effect | ID 0.1 mM | ID 1.0 mM | Effect | References |
|---|---|---|---|---|---|---|---|
| Monomers | |||||||
| (A1) | |||||||
|
| 2.7 | 3.6 | Moderate | 3.3 | 3.5 | Moderate | [ |
|
| 1.1 | 1.3 | Weak | 1.3 | 1.3 | Weak | [ |
|
| 1.1 | 1.3 | Weak | 0.7 | 0.9 | Weak | [ |
|
| 2.5 | 3.2 | Moderate | 2.4 | 2.9 | Weak | [ |
|
| 5.6 | 10.1 | Strongest | 5.2 | 6.9 | Strong | [ |
| (A2) | |||||||
|
| 1.5 | 3.2 | Moderate | 1.6 | 4.4 | Moderate | [ |
|
| 1.0 | 3.5 | Moderate | 1.0 | 6.3 | Strong | [ |
|
| 1.9 | 5.8 | Strong | 3.1 | 9.8 | Strongest | [ |
|
| 3.1 | 13.8 | Strongest | 4.4 | 29.3 | Strongest | [ |
| (A3) | |||||||
|
| 1.3 | 3.2 | Moderate | 1.3 | 5.0 | Moderate | Tw |
|
| 1.1 | 3.5 | Moderate | 1.0 | 5.5 | Strong | [ |
|
| 1.9 | 3.8 | Moderate | 1.5 | 6.8 | Strong | Tw |
|
| 1.7 | 5.0 | Strong | 4.0 | 8,8 | Strong | [ |
|
| 1.5 | 4.3 | Moderate | 2.7 | 8.8 | Strong | [ |
|
| 1.9 | 4.2 | Moderate | 2.6 | 8.8 | Strong | [ |
| Dimers | |||||||
|
| 5.2 | 7.2 | Strong | 2.1 | 3.2 | Moderate | [ |
|
| 1.8 | 3.3 | Moderate | 1.8 | 4.2 | Moderate | [ |
|
| 2.6 | 13.5 | Strongest | 2.1 | 29.3 | Strongest | [ |
|
| 2.9 | 12.8 | Strongest | 3.1 | 11.0 | Strongest | [ |
|
| 1.6 | 3.8 | Moderate | 1.6 | 4.8 | Moderate | Tw |
|
| 1.6 | 5.8 | Strong | 1.6 | 8.8 | Strong | [ |
|
| 2.1 | 6.4 | Strong | 1.7 | 8.0 | Strong | Tw |
|
| 1.6 | 4.9 | Moderate | 1.7 | 6.3 | Strong | [ |
|
| 1.4 | 5.8 | Strong | 2.0 | 5.9 | Strong | [ |
|
| 1.7 | 6.9 | Strong | 1.8 | 9.8 | Strongest | [ |
Tw—this work; DVa, DApo, DEu are not soluble in lipid substrate, M6, M7, D6, D7, DisoEu are studied only theoretically.
Figure 1Effect of the substituents in the side chain of selected A1–A3 ortho-methoxyphenols expressed in terms of PF and ID values.
Figure 2Effect of concentration for selected monomers and dimers.
Figure 3Effect of biphenyl structure. The main kinetic parameters evaluated for dimer/monomer pairs.
Scheme 1Reaction mechanism for Eu and Cr.
Scheme 2Reaction mechanism for ortho-methoxyphenols (group A2) during lipid autoxidation reaction with lipid peroxide radicals, reaction of homo-recombination of phenoxyl radical (AO•), resonance structures of AO• (O- and C-centered radicals) and quinolide peroxides formation.
Scheme 3Reaction mechanism for ortho-methoxyphenols (group A3) during lipid autoxidation: reactions with lipid peroxide radicals, reactions of homo-recombination of phenoxyl radical (AO•), resonance structures of AO• (O- and C-centered radicals) and quinolide peroxide formation.
The main kinetic parameters of the chain-breaking activity of ortho-hydroxyphenols and their dimers during lipid autoxidation.
| Abbr. | PF | PF | Activity | ID | ID | Activity | Refs. |
|---|---|---|---|---|---|---|---|
|
| 6.7 | 33.1 | Strongest | 9.3 | 28.0 | Strongest | [ |
|
| 14.6 | 46.2 | Strongest | 43.8 | 58.7 | Strongest | tw |
|
| 8.2 | 15.2 | Strongest | n.d. | n.d. | - | tw |
|
| 6.7 | 20.7 | Strongest | 13.7 | 36.7 | Strongest | tw |
|
| 12.5 | 15.2 | Strongest | n.d. | n.d. | - | tw |
|
| n.s. | n.s. | - | n.s. | n.s. | - | tw |
|
| n.s. | n.s. | - | n.s. | n.s. | - | tw |
|
| n.s. | n.s. | - | n.s. | n.s. | - | tw |
n.s. refers to not soluble in lipid substrate, n.d. means not determined, tw pertains to this work.
Scheme 4Reaction mechanism for ortho-hydroxyphenols.
Figure 4Time profiles of the relative CL intensity (I/I∞) measured during the oxidation of ethylbenzene in the aerated chlorobenzene solution (26% vol.) initiated by AIBN at the rate of RIN = 5.1 × 10–9 M s−1 and 50 °C upon introduction of 1.2 × 10−5 M of curcumin.
The values of the effective rate constant (kA) of scavenging the peroxyl radicals of ethylbenzene by antioxidants.
| Abbr. | Compound | |
|---|---|---|
|
|
| (4.3 ± 0.3) × 104 |
|
|
| (1.6 ± 0.1) × 104 |
|
|
| (4.1 ± 0.3) × 104 |
|
|
| (1.7 ± 0.1) × 104 |
|
|
| (4.2 ± 0.3) × 104 |
|
|
| (2.6 ± 0.3) × 104 |
|
|
| (5.1 ± 0.3) × 104 |
|
|
| (2.4 ± 0.3) × 104 |
|
|
| (3.7 ± 0.3) × 104 |
Figure 5Optimized geometry of the most stable conformers. (Green curved line) OH groups whose BDEs are reported in Table S4 and presented in Figure 6; (yellow orange circle) structural fragment where protopropic tautomerism can occur.
Figure 6DFT calculated BDEs for curcumin, natural and synthetic antioxidants.
In silico predictions of important ADME/Tox properties of the investigated compounds.
| Compound | logP | logS | MAD (%HIA) | BBB | P-gp | Mammal Hepato-Toxicity | Mammal Carcino-Genicity | Hazard Category |
|---|---|---|---|---|---|---|---|---|
| A1 | ||||||||
|
| 1.83 | −1.70 | 27.7 (28%) | P | 0.05 | A | IV | |
|
| 2.57 | −3.31 | 0.3 (0%) | P | 0.11 * | A | IV | |
|
| 1.29 | −1.41 | 11.5 (11%) | W | 0.04 | IV | ||
|
| 1.53 | −2.20 | 1.0 (1%) | N | 0.08 | V | ||
|
| 1.4 | −1.70 | 13.8 (14%) | P | 0.06 | IV | ||
|
| 1.83 | −3.13 | 0.2 (0%) | N | 0.22 | IV | ||
|
| 2.48 | −2.08 | 11.3 (11%) | P | 0.06 |
| IV | |
|
| 3.43 | −4.27 | 0.0 (0%) | P | 0.16 * | A | V | |
|
| 2.55 | −2.30 | 9.3 (9%) | P | 0.05 | A | IV | |
|
| 3.60 | −4.56 | 0.0 (0%) | P | 0.13 | A | V | |
| A2 | ||||||||
|
| 1.68 | 0.71 | 139.9 (100%) | N | 0.02 | V | ||
|
| 1.86 | 0.41 | 35.0 (35%) * | N | 0.02 * | V | ||
|
| 1.69 | −2.02 | 14.9 (15%) | P | 0.10 | IV | ||
|
| 2.13 | −3.97 | 0.1 (0%) | P | 0.57 * | V | ||
|
| 1.62 | −2.35 | 2.9 (3%) | P | 0.09 * | IV | ||
|
| 2.32 | −4.74 | 0.0 (0%) | W | 0.60 * | V | ||
|
| 1.98 | −2.67 | 1.8 (2%) | P | 0.10 * | IV | ||
|
| 1.03 | −2.56 | 1.2 (1%) | P | 0.14 * | IV | ||
|
| 1.75 | −5.01 | 0.0 (0%) | N | 0.70 * | V | ||
|
| 2.64 | −3.63 | 0.4 (0%) | P | 0.40 | V | ||
| A3 | ||||||||
|
| 1.27 | 0.71 | 529.1 (100%) | N | 0.03 | A, B | V | |
|
| 1.17 | 0.41 | 34.3 (34%) * | N | 0.02 | A, B | V | |
|
| 1.1 | −1.44 | 55.6 (56%) | P | 0.07 | A | V | |
|
| 1.06 | −2.96 | 1.9 (2%) | W | 0.21 * | A | V | |
|
| 1.18 | −2.30 | 11.3 (11%) | P | 0.08 | A | IV | |
|
| 1.83 | −4.80 | 0.2 (0%) | W | 0.39 * | A | V | |
|
| 2.41 | −3.81 | 3.7 (4%) | P | 0.19 * | A | IV | |
|
| 4.16 | −7.26 | 0.0 (0%) * | N | 0.76 * | A | IV | |
|
| 2.86 | −3.89 | 1.4 (1%) | P | 0.22 * | A | IV | |
|
| 4.76 | −7.69 | 0.0 (0%) * | N | 0.84 * | A | IV | |
|
| 3.83 | −4.64 | 0.4 (0%) | P | 0.42 * | A | V | |
|
| 7.2 | -8.95 | 0.0 (0%) * | N | 0.94 * | A | V | |
| B1 | ||||||||
|
| 1.9 | −1.00 | 9.7 (10%) | P | 0.04 | A | C | IV |
|
| 2.92 | −2.85 | 0.1 (0%) | P | 0.06 | A | IV | |
| B2 | ||||||||
|
| 1.68 | −1.03 | 14.4 (14%) | P | 0.04 | C | IV | |
|
| 1.92 | −2.86 | 0.3 (0%) | P | 0.12 * | V | ||
|
| 1.35 | 0.74 | 124.7 (100%) | W | 0.01 | C | V | |
|
| 1.32 | 0.45 | 10.8 (11%) * | N | 0.00 | V | ||
| B3 | ||||||||
|
| 0.83 | 0.74 | 476.3 (100%) | N | 0.02 | A, B | C | IV |
|
| 0.46 | 0.44 | 10.7 (11%) * | N | 0.01 | A, B | V | |
Legend: Lipophilicity (logP); water solubility (logS at pH 7.4); MAD (maximum absorbable dose) and based on it %HIA (human intestinal absorption, % of 100 mg dose); BBB (blood–brain barrier) penetration: P—penetrant, N—non-penetrant, W—weak penetrant; mammal hepatotoxicity: A—“para-alkylphenol or derivative”, B—“2-arylacetic or 3-arylpropionic acid”; mammal carcinogenicity: C—“catechol with no more than 15 non-hydrogen atoms”; hazard category based on probabilistic categorization of acute systemic toxicity (based on LD50). *—the compound is outside the applicability domain of the model; bold text—“probable” level of likelihood.